Skip to main content Accessibility help
×
Home

Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders

  • G. Martinotti (a1), M. Pettorruso (a2), R. Santacroce (a1), G. Biggio (a3) and M. Di Giannantonio (a1)...

Abstract

Introduction

Agomelatine is a novel antidepressant whose role in the treatment of depression is growing. Brain-derived neurotrophic factor (BDNF) is a neurotrophin, acting on synaptic plasticity and maintaining midbrain dopaminergic and cholinergic neurons. Patients with depressive disorders exhibit diminished plasma BDNF levels, usually increased by antidepressant treatment.

Objectives

Aim of the study was to investigate the effects produced by chronic agomelatine treatment on BDNF serum levels in depressed patients.

Methods

27 depressed patients and 29 healthy controls (HC) were enrolled in the study. Clinical assessment was performed at T0, T1 (after 2 weeks) and T2 (after 8 weeks). After screening period, patients were administered agomelatine (25 mg/day, per os); in the case of no clinical response, the dosage could be increased to 50 mg/day, At T0 and T2, venous blood samples were collected.

Results

Mann-Whitney U-test was performed to compare baseline BDNF levels between patients and HC. Baseline BDNF levels were found to be significantly lower in depressed individuals. During the study period, Friedman's test showed significant changes in BDNF serum levels. Their increase was correlated with depressive symptoms, as measured by reduction in HDRS scores. Also, responders showed a significant difference in BDNF levels after 2-week agomelatine treatment, while non-responders showed no difference.

Conclusions

our study demonstrates that patients affected by Depressive Disorders show an increase in BDNF serum concentration after a two-weeks therapy with agomelatine, with the clinical improvement of depression, anhedonia and anxiety significantly correlated with the levels of the neurotrophin.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders
      Available formats
      ×

Copyright

Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders

  • G. Martinotti (a1), M. Pettorruso (a2), R. Santacroce (a1), G. Biggio (a3) and M. Di Giannantonio (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Correlation Between Use of Agomelatine and Bdnf Levels in the Treatment of Depressive Disorders

  • G. Martinotti (a1), M. Pettorruso (a2), R. Santacroce (a1), G. Biggio (a3) and M. Di Giannantonio (a1)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *